Insulin analogue: Difference between revisions

Insulin analogue
	File:Insulin structure.png
INN
Drug class	Insulin preparation
Routes of administration	Subcutaneous injection, IV (for some rapid-acting analogs)
Pregnancy category	Varies by analog
Bioavailability	Varies
Metabolism	Liver, kidney
Elimination half-life	Varies (minutes to hours)
Excretion	Kidney
Legal status	Rx-only
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Newer edit →

Revision as of 05:59, 13 March 2025

Insulin analogs are modified forms of human insulin designed to improve pharmacokinetics and pharmacodynamics, providing better glycemic control for people with diabetes mellitus. These synthetic insulins have altered amino acid sequences, affecting their absorption, distribution, metabolism, and elimination (ADME) properties.

Types of Insulin Analogs

Insulin analogs are classified into rapid-acting, long-acting, and ultra-long-acting formulations based on their onset and duration of action.

Rapid-acting Insulin Analogs

Used to control postprandial blood glucose spikes.

Rapid-Acting Insulin Analogs
Name	Brand Names	Onset of Action	Peak Effect	Duration
Insulin lispro	Humalog, Admelog	~15 min	1–2 hours	3–5 hours
Insulin aspart	NovoLog, Fiasp	~10–20 min	1–3 hours	3–5 hours
Insulin glulisine	Apidra	~15 min	1–2 hours	3–5 hours

Long-acting and Ultra-long-acting Insulin Analogs

Used to maintain basal insulin levels throughout the day.

Long-Acting and Ultra-Long-Acting Insulin Analogs
Name	Brand Names	Onset of Action	Peak Effect	Duration
Insulin glargine	Lantus, Toujeo, Basaglar	~1–2 hours	No significant peak	18–24 hours
Insulin detemir	Levemir	~1–2 hours	Minimal peak	12–24 hours
Insulin degludec	Tresiba	~1 hour	No significant peak	>42 hours

Mechanism of Action

Insulin analogs work by: 1. Binding to the insulin receptor (IR) on target cells (liver, muscle, adipose). 2. Stimulating glucose uptake via GLUT4 transporters. 3. Inhibiting hepatic glucose production and promoting glycogen synthesis. 4. Suppressing lipolysis and proteolysis.

The modifications in insulin analogs affect their absorption rate and receptor affinity, providing a more physiological insulin profile.

Advantages of Insulin Analogs

Compared to human insulin, insulin analogs offer:

Faster onset (e.g., rapid-acting analogs for meal coverage).
Prolonged basal action (e.g., ultra-long-acting insulin reduces nocturnal hypoglycemia).
Lower risk of hypoglycemia (especially long-acting formulations).
More predictable absorption with less variability.

Clinical Indications

Insulin analogs are used for:

Type 1 diabetes mellitus (T1DM) – Requires both basal and bolus insulin.
Type 2 diabetes mellitus (T2DM) – Used when oral hypoglycemic agents fail.
Gestational diabetes mellitus (GDM) – Preferred over human insulin for better glycemic control.
Diabetic ketoacidosis (DKA) – IV insulin analogs used in critical care settings.

Comparison with Human Insulin

Comparison of Insulin Analogs vs. Human Insulin
Feature	Human Insulin	Insulin Analogs
Onset of action	Slower (30–60 min)	Faster (10–15 min for rapid-acting)
Duration	Shorter or longer (varies)	More predictable
Risk of hypoglycemia	Higher	Lower (especially nocturnal hypoglycemia)
Absorption variability	Higher	Lower

Potential Side Effects

Common side effects include:

Hypoglycemia (risk varies by type of insulin).
Weight gain (due to anabolic effects of insulin).
Injection site reactions (e.g., lipodystrophy).
Allergic reactions (rare but possible).
Hypokalemia (can lead to cardiac arrhythmias).

Special Considerations

Renal impairment – Adjust dosing for patients with chronic kidney disease (CKD).
Liver dysfunction – Insulin metabolism is reduced in hepatic impairment.
Pregnancy and lactation – Some analogs (e.g., insulin detemir) are FDA-approved for pregnancy.

Future Developments

Research is ongoing for:

Oral insulin formulations (to improve compliance).
Smart insulin pumps (automated insulin delivery systems).
Ultra-rapid insulins (faster onset for meal-time control).

@@ Line 1: / Line 1: @@
-#REDIRECT [[insulin analog]]
+{{Infobox drug
+| name = Insulin analog
+| image = Insulin structure.png
+| caption = Structure of human insulin, which serves as the basis for insulin analogs.
+| pronounce =
+| tradename = [[Humalog]], [[NovoLog]], [[Lantus]], [[Levemir]], [[Tresiba]], [[Fiasp]], [[Apidra]], and others
+| Drugs.com =
+| MedlinePlus =
+| pregnancy_category = [[Pregnancy category|Varies by analog]]
+| legal_status = [[Prescription drug|Rx-only]]
+| routes_of_administration = [[Subcutaneous injection]], [[Intravenous therapy|IV]] (for some rapid-acting analogs)
+| bioavailability = Varies
+| metabolism = [[Liver]], [[kidney]]
+| elimination_half-life = Varies (minutes to hours)
+| excretion = [[Kidney]]
+| class = [[Insulin]] preparation
+| ATC_prefix = A10
+| ATC_suffix = AE04
+}}
+'''Insulin analogs''' are modified forms of [[human insulin]] designed to improve '''pharmacokinetics and pharmacodynamics''', providing better '''glycemic control''' for people with [[diabetes mellitus]]. These synthetic insulins have altered '''amino acid sequences''', affecting their '''absorption, distribution, metabolism, and elimination (ADME)''' properties.
+== Types of Insulin Analogs ==
+Insulin analogs are classified into '''rapid-acting, long-acting, and ultra-long-acting''' formulations based on their onset and duration of action.
+=== Rapid-acting Insulin Analogs ===
+Used to control '''postprandial blood glucose spikes'''.
+{| class="wikitable"
+|+ Rapid-Acting Insulin Analogs
+|-
+! Name !! Brand Names !! Onset of Action !! Peak Effect !! Duration
+|-
+| '''[[Insulin lispro]]''' || [[Humalog]], [[Admelog]] || ~15 min || 1–2 hours || 3–5 hours
+|-
+| '''[[Insulin aspart]]''' || [[NovoLog]], [[Fiasp]] || ~10–20 min || 1–3 hours || 3–5 hours
+|-
+| '''[[Insulin glulisine]]''' || [[Apidra]] || ~15 min || 1–2 hours || 3–5 hours
+|}
+=== Long-acting and Ultra-long-acting Insulin Analogs ===
+Used to maintain '''basal insulin levels''' throughout the day.
+{| class="wikitable"
+|+ Long-Acting and Ultra-Long-Acting Insulin Analogs
+|-
+! Name !! Brand Names !! Onset of Action !! Peak Effect !! Duration
+|-
+| '''[[Insulin glargine]]''' || [[Lantus]], [[Toujeo]], [[Basaglar]] || ~1–2 hours || No significant peak || 18–24 hours
+|-
+| '''[[Insulin detemir]]''' || [[Levemir]] || ~1–2 hours || Minimal peak || 12–24 hours
+|-
+| '''[[Insulin degludec]]''' || [[Tresiba]] || ~1 hour || No significant peak || >42 hours
+|}
+== Mechanism of Action ==
+Insulin analogs work by:
+. Binding to the '''insulin receptor (IR)''' on target cells (liver, muscle, adipose).
+. Stimulating '''glucose uptake''' via '''GLUT4 transporters'''.
+. Inhibiting '''hepatic glucose production''' and promoting '''glycogen synthesis'''.
+. Suppressing '''lipolysis and proteolysis'''.
+The '''modifications''' in insulin analogs affect their '''absorption rate and receptor affinity''', providing a '''more physiological insulin profile'''.
+== Advantages of Insulin Analogs ==
+Compared to '''human insulin''', insulin analogs offer:
+* '''Faster onset''' (e.g., rapid-acting analogs for meal coverage).
+* '''Prolonged basal action''' (e.g., ultra-long-acting insulin reduces nocturnal hypoglycemia).
+* '''Lower risk of hypoglycemia''' (especially '''long-acting formulations''').
+* '''More predictable absorption''' with '''less variability'''.
+== Clinical Indications ==
+Insulin analogs are used for:
+* '''Type 1 diabetes mellitus (T1DM)''' – Requires '''both basal and bolus insulin'''.
+* '''Type 2 diabetes mellitus (T2DM)''' – Used when '''oral hypoglycemic agents''' fail.
+* '''Gestational diabetes mellitus (GDM)''' – Preferred over human insulin for '''better glycemic control'''.
+* '''Diabetic ketoacidosis (DKA)''' – '''IV insulin analogs''' used in critical care settings.
+== Comparison with Human Insulin ==
+{| class="wikitable"
+|+ Comparison of Insulin Analogs vs. Human Insulin
+|-
+! Feature !! Human Insulin !! Insulin Analogs
+|-
+| '''Onset of action''' || Slower (30–60 min) || Faster (10–15 min for rapid-acting)
+|-
+| '''Duration''' || Shorter or longer (varies) || More predictable
+|-
+| '''Risk of hypoglycemia''' || Higher || Lower (especially nocturnal hypoglycemia)
+|-
+| '''Absorption variability''' || Higher || Lower
+|}
+== Potential Side Effects ==
+Common side effects include:
+* '''Hypoglycemia''' (risk varies by type of insulin).
+* '''Weight gain''' (due to anabolic effects of insulin).
+* '''Injection site reactions''' (e.g., lipodystrophy).
+* '''Allergic reactions''' (rare but possible).
+* '''[[Hypokalemia]]''' (can lead to cardiac arrhythmias).
+== Special Considerations ==
+* '''Renal impairment''' – Adjust dosing for patients with '''chronic kidney disease (CKD)'''.
+* '''Liver dysfunction''' – Insulin metabolism is reduced in '''hepatic impairment'''.
+* '''Pregnancy and lactation''' – Some analogs (e.g., insulin detemir) are '''FDA-approved for pregnancy'''.
+== Future Developments ==
+Research is ongoing for:
+* '''Oral insulin formulations''' (to improve compliance).
+* '''Smart insulin pumps''' (automated insulin delivery systems).
+* '''Ultra-rapid insulins''' (faster onset for meal-time control).
+== See Also ==
+* [[Diabetes mellitus]]
+* [[Insulin pump]]
+* [[Hypoglycemia]]
+* [[Continuous glucose monitoring]]
+* [[Insulin therapy]]
+[[Category:Diabetes]]
+[[Category:Insulin]]
+[[Category:Endocrinology]]
+[[Category:Drugs acting on the endocrine system]]